CLINICAL EVALUATION OF CB 1348 IN LEUKEMIAS AND LYMPHOMAS
- 1 April 1958
- journal article
- research article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 68 (3), 979-995
- https://doi.org/10.1111/j.1749-6632.1958.tb42654.x
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- CHLORAMBUCIL IN TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA AND CERTAIN LYMPHOMASJAMA, 1956
- Evaluation of CB 1348 in Hodgkin's Disease and Allied DisordersArchives of Internal Medicine, 1956
- Early experience withp-(N,N-di-2-chloroethyl)-aminophenylbutyric acid (CB 1348), a new chemotherapeutic agent effective in the treatment of chronic lymphocytic leukemiaCancer, 1956
- Clinical Trials of p-(Di-2-chloroethylamine)-phenylbutyric Acid (CB 1348) in Malignant LymphomaBMJ, 1955
- Experimental and Clinical Aspects of the Action of Various Carboxylic Acid Derivatives in the Aromatic Nitrogen Mustard SeriesPublished by Wiley ,1954
- UNUSUAL TOXICITY TO TRIETHYLENE MELAMINE IN A CASE OF CHRONIC MYELOGENOUS LEUKEMIAAnnals of Internal Medicine, 1953
- Triethylene Melamine in Human Malignant DiseaseBMJ, 1953
- RADIOACTIVE PHOSPHORUS, P-32 - A 6-YEAR CLINICAL EVALUATION OF INTERNAL RADIATION THERAPY1947
- NITROGEN MUSTARD THERAPYJAMA, 1946
- NITROGEN MUSTARD THERAPYJAMA, 1946